Serum IL-17 levels are higher in critically ill patients with AKI and associated with worse outcomes

dc.contributor.authorCollett, Jason A.
dc.contributor.authorOrtiz‑Soriano, Victor
dc.contributor.authorLi, Xilong
dc.contributor.authorFlannery, Alexander H.
dc.contributor.authorToto, Robert D.
dc.contributor.authorMoe, Orson W.
dc.contributor.authorBasile, David P.
dc.contributor.authorNeyra, Javier A.
dc.contributor.departmentAnatomy, Cell Biology and Physiology, School of Medicine
dc.date.accessioned2023-06-13T13:12:40Z
dc.date.available2023-06-13T13:12:40Z
dc.date.issued2022-04-14
dc.description.abstractBackground: Interleukin-17 (IL-17) antagonism in rats reduces the severity and progression of AKI. IL-17-producing circulating T helper-17 (TH17) cells is increased in critically ill patients with AKI indicating that this pathway is also activated in humans. We aim to compare serum IL-17A levels in critically ill patients with versus without AKI and to examine their relationship with mortality and major adverse kidney events (MAKE). Methods: Multicenter, prospective study of ICU patients with AKI stage 2 or 3 and without AKI. Samples were collected at 24-48 h after AKI diagnosis or ICU admission (in those without AKI) [timepoint 1, T1] and 5-7 days later [timepoint 2, T2]. MAKE was defined as the composite of death, dependence on kidney replacement therapy or a reduction in eGFR of ≥ 30% from baseline up to 90 days following hospital discharge. Results: A total of 299 patients were evaluated. Patients in the highest IL-17A tertile (versus lower tertiles) at T1 had higher acuity of illness and comorbidity scores. Patients with AKI had higher levels of IL-17A than those without AKI: T1 1918.6 fg/ml (692.0-5860.9) versus 623.1 fg/ml (331.7-1503.4), p < 0.001; T2 2167.7 fg/ml (839.9-4618.9) versus 1193.5 fg/ml (523.8-2198.7), p = 0.006. Every onefold higher serum IL-17A at T1 was independently associated with increased risk of hospital mortality (aOR 1.35, 95% CI: 1.06-1.73) and MAKE (aOR 1.26, 95% CI: 1.02-1.55). The highest tertile of IL-17A (vs. the lowest tertile) was also independently associated with higher risk of MAKE (aOR 3.03, 95% CI: 1.34-6.87). There was no effect modification of these associations by AKI status. IL-17A levels remained significantly elevated at T2 in patients that died or developed MAKE. Conclusions: Serum IL-17A levels measured by the time of AKI diagnosis or ICU admission were differentially elevated in critically ill patients with AKI when compared to those without AKI and were independently associated with hospital mortality and MAKE.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationCollett JA, Ortiz-Soriano V, Li X, et al. Serum IL-17 levels are higher in critically ill patients with AKI and associated with worse outcomes. Crit Care. 2022;26(1):107. Published 2022 Apr 14. doi:10.1186/s13054-022-03976-4en_US
dc.identifier.urihttps://hdl.handle.net/1805/33711
dc.language.isoen_USen_US
dc.publisherBMCen_US
dc.relation.isversionof10.1186/s13054-022-03976-4en_US
dc.relation.journalCritical Careen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0*
dc.sourcePMCen_US
dc.subjectIL-17en_US
dc.subjectAcute kidney injuryen_US
dc.subjectCritical careen_US
dc.subjectMortalityen_US
dc.subjectMajor adverse kidney eventsen_US
dc.titleSerum IL-17 levels are higher in critically ill patients with AKI and associated with worse outcomesen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
13054_2022_Article_3976.pdf
Size:
1.14 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: